Positive experience of the usage of Rituximab in management of refractory myasthenia gravis in Russia

A subset of patients (15 to 20%) with myasthenia gravis (MG) remains refractory to standard types of treatment. Analysis of efficiency of rituximab, a chimeric monoclonal antibody to surface antigen of B lymphocytes (CD20), in 16 patients suffering from refractory MG was performed. In all cases, the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: N. I. Shcherbakova, N. A. Suponeva, V. V. Shvedkov, A. A. Shabalina, M. V. Kostyreva, V. A. Rudnichenko, O. I. Galkina
Natura: Artigo
Lingua:Russo
Pubblicazione: ABV-press 2015-09-01
Serie:Nervno-Myšečnye Bolezni
Soggetti:
refractory myasthenia
rituximab
selective b cell targeted therapy
b-cell depletion (cd20)
variations of autoantibodies to acetylcholine receptor (achr) levels
achr positive myasthenia gravis
qmg score
mgfa clinical classification
Accesso online:https://nmb.abvpress.ru/jour/article/view/124
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi